Trial Profile

COLONYVAQ™-CRC, a Physics-aware, Quantum-Classical AI-Guided Personalized Neoantigen Peptide Vaccine, Administered in Combination With Standard Adjuvant Oxaliplatin-based Chemotherapy (mFOLFOX6 or CAPOX) and Nivolumab 3 mg/kg in Patients With Completely Resected Stage III Microsatellite-stable (MSS)

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 16 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Colonyvaq (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Nivolumab; Oxaliplatin
Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
Focus Adverse reactions
Acronyms COLONYVAQ-CRC
Sponsors Biogenea Pharmaceuticals

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com